Voxtalisib(XL765)治疗复发或难治性非霍奇金淋巴瘤或慢性淋巴细胞白血病:一项开放标签2期试验
这项非随机、开放标签2期试验在6个国家30个肿瘤门诊纳入167例复发或难治性淋巴瘤或慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,口服voxtalisib 50 mg每日两次。164例可评估疗效者中30例(18.3%)总体缓解,滤泡性淋巴瘤缓解率41.3%,其他亚型有限;安全性可接受。
要点
- voxtalisib 50 mg每日两次在滤泡性淋巴瘤中显示较好疗效(41.3%缓解),其他亚型缓解率低。
- 最常见不良事件为腹泻(35%)、乏力(32%)、恶心(27%),3级及以上贫血12%。
- 严重不良事件发生率为58.1%,安全性特征与既往研究一致。
核心结论
- voxtalisib 50 mg口服每日两次安全性可接受,在滤泡性淋巴瘤患者中疗效有前景,但在套细胞淋巴瘤、弥漫大B细胞淋巴瘤或慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中疗效有限。
研究设计与样本
- 非随机、开放标签2期试验,在美国、比利时、德国、法国、荷兰和澳大利亚的30个肿瘤门诊进行。
- 纳入年龄≥18岁、ECOG体能状态评分≤2、复发或难治性套细胞淋巴瘤、滤泡性淋巴瘤、弥漫大B细胞淋巴瘤或慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。
- 治疗为voxtalisib 50 mg口服每日两次,28天连续给药周期,直至疾病进展或不可接受的毒性。
- 主要终点为各疾病特异性队列中达到总体缓解(完全缓解或部分缓解)的患者比例。
- 2011年10月19日至2013年7月24日共入组167例患者:套细胞淋巴瘤42例,滤泡性淋巴瘤47例,弥漫大B细胞淋巴瘤42例,慢性淋巴细胞白血病/小淋巴细胞淋巴瘤36例。
主要发现
- 164例可评估疗效患者中,30例(18.3%)达到总体缓解(部分缓解22例,完全缓解8例)。
- 滤泡性淋巴瘤46例中19例(41.3%)缓解,套细胞淋巴瘤42例中5例(11.9%)缓解,弥漫大B细胞淋巴瘤41例中2例(4.9%)缓解,慢性淋巴细胞白血病/小淋巴细胞淋巴瘤35例中4例(11.4%)缓解。
- 淋巴瘤患者既往抗癌方案中位数为3(IQR 2-4),慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者为4(IQR 2-5)。
- 最常见不良事件:腹泻59/167例(35%)、乏力53例(32%)、恶心45例(27%)、发热44例(26%)、咳嗽40例(24%)、食欲下降35例(21%)。
- 最常见3级或更差不良事件:贫血20/167例(12%)、肺炎14例(8%)、血小板减少13例(8%);严重不良事件97/167例(58.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with relapsed or refractory lymphoma or chronic lymphocytic leukaemia have a poor prognosis. Therapies targeting more than one isoform of PI3K, as well as mTOR, might increase antitumour activity. We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. METHODS: We did a non-randomised, open-label, phase 2 trial at 30 oncology clinics in the USA, Belgium, Germany, France, the Netherlands, and Australia. Patients aged 18 years or older with Eastern Cooperative Oncology Group (EGOG) performance status score of 2 or lower and relapsed or refractory mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma were enrolled and treated with voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity. The primary endpoint was the proportion of patients in each disease-specific cohort who achieved an overall response, defined as a complete response or partial response. All patients who received more than 4 weeks of treatment and who completed a baseline and at least one post-baseline tumour assessment were analysed for efficacy and all patients were analysed for safety. This study is registered with ClinicalTrials.gov, number NCT01403636, and has been completed. FINDINGS: Between Oct 19, 2011, and July 24, 2013, 167 patients were enrolled (42 with mantle cell lymphoma, 47 with follicular lymphoma, 42 with diffuse large B-cell lymphoma, and 36 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The median number of previous anticancer regimens was three (IQR 2-4) for patients with lymphoma and four (2-5) for patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Of 164 patients evaluable for efficacy, 30 (18·3%) achieved an overall response (partial, n=22; complete, n=8); 19 (41·3%) of 46 with follicular lymphoma, five (11·9%) of 42 with mantle cell lymphoma, two (4·9%) of 41 with diffuse large B-cell lymphoma, and four (11·4%) of 35 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The safety profile was consistent with that of previous studies of voxtalisib. The most frequently reported adverse events were diarrhoea (in 59 [35%] of 167 patients), fatigue (in 53 [32%]), nausea (in 45 [27%]), pyrexia (in 44 [26%,]), cough (in 40 [24%]), and decreased appetite (in 35 [21%]). The most frequently reported grade 3 or worse adverse events were anaemia (in 20 [12%] of 167 patients), pneumonia (in 14 [8%]), and thrombocytopenia (in 13 [8%]). Serious adverse events occurred in 97 (58·1%) of 167 patients. INTERPRETATION: Voxtalisib 50 mg given orally twice daily had an acceptable safety profile, with promising efficacy in patients with follicular lymphoma but limited efficacy in patients with mantle cell lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. FUNDING: Sanofi.
引用
- Brown JR, Hamadani M, Hayslip J, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018. PMID: 29550382. doi:10.1016/S2352-3026(18)30030-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。